Login
$IVVD
$0.55 +$0.01 (2.27%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
William Duke, Jr.
Chief Financial Officer and principal executive officer
53 Not stated Not stated $2,141,222
Marc Elia Also a director
Chief Executive Officer
Title from the Form 8-K dated Aug 30, 2026
50 Not stated Not stated Not reported
Robert Allen
Chief Scientific Officer
57 Since 2023
3 years
Not stated Not reported
Jill Andersen
Chief Legal Officer and Corporate Secretary
53 Since 2021
5 years
Not stated $2,486,155
Julie Green
Chief Human Resources Officer
51 Since 2024
2 years
2022 Not reported
Timothy Lee
Chief Commercial Officer
52 Since 2024
2 years
Not stated $2,095,311
Michael Mina
CMO and Chief Epidemiologist
Title from the Form 3 dated Jul 31, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 6, 2026 · updated by the 8-K of Sep 1, 2026

Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
3.8 years
from year joined
CEO also chairs the board
No
Marc Elia
Director Age On board Independent Committees Other public boards 2025 pay Source
Marc Elia
50 2022
4 years
Independent None stated Fractyl Health, Inc. $125,960
Ajay Royan
46 2020
6 years
Independent
Nominating and Corporate Governance Committee · Chair
Fractyl Health, Inc. $110,162
Tamsin Berry
45 2022
4 years
Independent
Audit Committee
None stated $87,960
Paul B. Bolno, M.D.
52 2025
1 year
Independent
Compensation Committee
Wave Life Sciences Ltd. $134,351
Terrance McGuire
70 2020
6 years
Independent None stated Seer, Inc. $84,460
Kevin F. McLaughlin
69 2024
2 years
Independent
Audit Committee
Vericel Corporation $101,614
Ian Sheffield Joined Aug 30, 2026
- - -
Compensation Committee Audit Committee
- -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

10 disclosed in the proxy filed Apr 6, 2026
Population Health Partners, L.P. (PHP)
Amount not stated

Common stock warrant issued to PHP to purchase up to 6,824,712 shares at $3.48 per share, vesting in tranches on market capitalization targets

Population Health Partners, L.P. (PHP)
Amount not stated

Master Services Agreement and related work order with PHP, in connection with which the PHP Warrant was issued

Adimab
Beneficial owner of 7.16% of our common stock; Terrance McGuire and Ajay Royan are members of our Board and the board of directors of Adimab
$40.0 million
July 2020

Assignment and License Agreement under which we issued 5,000,000 shares of Series A preferred stock to Adimab in consideration for assigned rights and license

Adimab
Beneficial owner of 7.16% of our common stock; Terrance McGuire and Ajay Royan are members of our Board and the board of directors of Adimab
$2.5 million
January 1, 2024 through December 31, 2025

Payments to Adimab in connection with the Adimab Assignment Agreement

Adimab
Beneficial owner of 7.16% of our common stock; Terrance McGuire and Ajay Royan are members of our Board and the board of directors of Adimab
$2.0 million and $0.5 million
2025 and 2024

Royalty payments to Adimab under the Adimab Assignment Agreement

Adimab
Beneficial owner of 7.16% of our common stock; Terrance McGuire and Ajay Royan are members of our Board and the board of directors of Adimab
$5.7 million
January 1, 2024 through December 31, 2025

Payments to Adimab under the Adimab Collaboration Agreement (quarterly fees, research and option fees)

Adimab
Beneficial owner of 7.16% of our common stock; Terrance McGuire and Ajay Royan are members of our Board and the board of directors of Adimab
$3.0 million
September 2022

Upfront consideration paid to Adimab for rights under the Platform Transfer Agreement

Adimab
Beneficial owner of 7.16% of our common stock; Terrance McGuire and Ajay Royan are members of our Board and the board of directors of Adimab
$4.0 million
January 1, 2024 through December 31, 2025

Annual Fee payments to Adimab under the Platform Transfer Agreement

Adimab
Beneficial owner of 7.16% of our common stock; Terrance McGuire and Ajay Royan are members of our Board and the board of directors of Adimab
Less than $0.1 million
January 1, 2024 through December 31, 2025

Payments to Adimab under the DNA Sequencing Services Agreement

Adimab
Beneficial owner of 7.16% of our common stock; Terrance McGuire and Ajay Royan are members of our Board and the board of directors of Adimab
Amount not stated
January 1, 2024 through December 31, 2025

LCMS Services Agreement with Adimab for molecular weight determination services; no payments made in the period

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support